Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast calculations
1.4 Data collection
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of influenza
3.2.1.2 Rising government health initiatives and immunization programs
3.2.1.3 Growing advancements in vaccine technology
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with vaccine development
3.2.2.2 Longer vaccine production timelines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Inactivated
5.3 Live attenuated
Chapter 6 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Quadrivalent
6.3 Trivalent
Chapter 7 Market Estimates and Forecast, By Technology, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Egg-based
7.3 Cell-based
Chapter 8 Market Estimates and Forecast, By Flu Type, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Seasonal
8.3 Pandemic
Chapter 9 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Pediatrics
9.3 Adults
Chapter 10 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 Injection
10.3 Nasal spray
Chapter 11 Market Estimates and Forecast, By End-User, 2018 – 2032 ($ Mn)
11.1 Key trends
11.2 Hospitals
11.2.1 Public
11.2.2 Private
11.3 Clinics
11.4 Other end-users
Chapter 12 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
12.1 Key trends
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Spain
12.3.5 Italy
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 Rest of Asia Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Middle East and Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 Rest of Middle East and Africa
Chapter 13 Company Profiles
13.1 AstraZeneca plc
13.2 CSL Limited
13.3 Merck & Co., Inc.
13.4 GlaxoSmithKline plc
13.5 Sanofi SA
13.6 Emergent BioSolutions
13.7 Sinovac Biotech Ltd.
13.8 Novartis AG
13.9 Gamma Vaccines Pty Ltd.
13.10 Viatris Inc.
